David Horrobin Patents

The following patents (which are in date order) list David Horrobin as one of the named inventors. Click on the patent numbers to get more details from the World Patent Office database (including the full text in most cases). Click on a company name to search for UK company registration details in the official database. You can search this page for words and phrases on this page by using the search function in your browser (Ctrl-F in Internet Explorer).

001

Compositions and use of γ-linolenic acids and related materials in association with zinc and/or β-lactam antibiotics to treat schizophrenia, obesity, menstrual disorders, skin disorders and other conditions.

Company: Efamol	Filed/Published: 17 Jan 1979
EP0003407	GLA and schizophrenia etc
US4302447	GLA and schizophrenia, obesity, menstrual and skin disorders (div A)
US4444755	GLA and skin disorders (div B)
US4393049	GLA and obesity (div C)
US4415554	GLA and menstrual disorders (div D)
US4273763	GLA and schizophrenia

002

Compositions and use of γ-linolenic and related materials with (i) zinc, β-lactam antibiotics or other materials enhancing physiological 1-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of cancer or inflammatory disorders.

Company: Verronmay	Filed/Published: 23 Apr 1979
EP0004770	Cancer/inflamm. disorders
US4309415	Cancer/inflamm. disorders
US4931468	Cancer/inflamm. (div a GLA/cancer)

003

A method for the treatment or prophylaxis of angina pectoris or myocardial infarction which consists of administering indomethacin or chloroquine. It has been found that angina pectoris and myocardial infarction may be susceptible to treatment by administration of substances which will inhibit the synthesis or action of prostaglandins, which it is believed to be the effect of administering indomethacin or chloroquine.

Company: Personal	Filed/Published: 14 May 1979
US4287202	Treatment for coronary disorders

004

A method for the treatment of anxiety which consists of administering dipyridamole or imidazole or a derivative thereof. It has been found that known anti-anxiety agents appear to act as competitive antagonists of thromboxane A2 (TXA2), and it is therefore believed that dipyridamole and imidazole, which inhibit the formation of TXA2, will be effective in the treatment of anxiety.

Company: Personal	Filed/Published: 24 Aug 1979
US4248872	Method for the treatment of anxiety

005

Compositions and use of γ-linolenic acid and related materials with ascorbic acid, or ethyl alcohol, or an opiate antagonist such as naloxone, nalorphine or levallorphan, for treating alcoholism or moderating the effects of taking alcohol.

Company: Efamol	Filed/Published: 8 May 1980
EP0019423	GLA and vitamin C etc
US4388324	GLA and vitamin C and alcoholism
US4535093	GLA and vitamin C and alcoholism

006

A pharmaceutical composition comprising γ-linolenic acid and/or dihomo-γ-linolenic acid together with a conjoint amount of a compound influencing the 1-series/2-series PG balance in the body in favour of 1-series PGs and selected from chloroquine and other 4-aminoquinolines including amodiaquine and hydroxychloroquine; diiodohydroxyquin and other 8-hydroxy and 8-aminoquinolines including iodochlorhydroxyquin, chiniofon, pentaquine, isopentaquine and primaquine; quinacrine (mepacrine) and other acridines; quinidine, quinine and procaine; emetine, metronidazole and other antiprotozoals (not already name above); and spironolactone and other modified steroids, alone or in an acceptable pharmaceutical vehicle.

Company: Efamol	Filed/Published: 3 Mar 1981
EP0078434	Oil + anti-malarials div
EP0035856	Oil + anti-malarials

007

A pharmaceutical composition comprising γ-linolenic acid and/or dihomo- γ-linolenic acid and a conjoint amount of thioproline or other administrable reverse transformer, for treatment of cancer.

Company: Efamol	Filed/Published: 3 Mar 1981
EP0037175	Pharmaceutical compositions

008

A method for the treatment and/or prophylaxis of the side-effects of lithium treatment in a subject suffering from manic-depressive psychosis, which method comprises administering to the subject an effective amount therefore of dihomo-γ-linolenic acid and/or a biosynthetic precursor thereof.

Company: Personal	Filed/Published: 7 Apr 1981
US4328243	Manic-depressive illnesses

009

A pharmaceutical composition for use in the treatment or prophylaxis of disorders of inflammation and immunity and disorders associated with smooth muscle spasm, comprising dihomo-γ-linolenic acid or a bioprescursor therof in conjunction with a physiologically acceptable lithium salt. Vitamin E and related tocopherols may optionally also be present in the composition.

Company: Personal	Filed/Published: 3 Feb 1982
EP0068854	Treatment for muscle disorders

010

A composition of an effective amount of (a) γ-linolenic acid and/or dihomo-γ-linolenic acid, optionally in association with linoleic and if desired other fat acids, said acids being used if desired as physiologically functional derivatives thereof, in conjunction with (b) an effective amount of one or more of natural or synthetic carotenoids or retinoids having, or giving rise in the body to compounds having, Vitamin A activity when used in therapy of a condition in which enhancement of 1-series PG production, or more broadly influence of the 1-series/2-series PG balance in the body in favour of 1-series PGs is required.

Company: Efamol	Filed/Published: 12 Jul 1982
EP0071357	GLA and vitamin A
US5324748	GLA and vitamin A

011

A pharmaceutical composition comprises one or more essential fatty acids such as γ-linolenic acid in conjunction with a bile salt binder or niacin or both. The compositions may be administered to reduce blood cholesterol levels.

Company: Efamol	Filed/Published: 8 Feb 1983
EP0087864	Pharmaceutical composition

012

A pharmaceutical composition comprises one or more essectial fatty acids, for example γ-linolenic acid, in conjunction with glutathione. The compositions may be used in the treatment of cancer or inflammatory disorders.

Company: Efamol	Filed/Published: 8 Feb 1983
EP0087865	Oil + glutathione

013

A pharmaceutical composition comprises one or more essential fatty acids, for example, γ-linolenic acid, in conjunction with rutin, troxerutin or other bioflanonoid. The composition is useful in the treatment of inflammation or defective T-lymphocyte function.

Company: Efamol	Filed/Published: 12 Apr 1983
EP0093516	Oil + rutin
US4888326	Oil + rutin

014

A pharmaceutical composition comprises one or more essential fatty acids, for example γ-linolenic acid, in conjunction with biotin. The compositions may be administered for treating inflammatory disorders.

Company: Efamol	Filed/Published: 7 Sep 1983
EP0087863	Oil + biotin

015

A pharmaceutical or dietary composition for use in the treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, comprising effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of alpha-linolenic acid (18:4n-3, 20:4n-3, 20:5n-5, 22:5n-3 or 22:6n-3) as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

Company: Efamol	Filed/Published: 24 Jan 1984
EP0115419	Fish oil (atopic disorders)
EP0440307	Fish oil div b (cancer)
EP0440308	Fish oil div c (diabetes)
EP0440309	Fish oil div d (alcoholism)
US4681896	Fish oil (atopic disorders)
US4868212	Fish oil div a animals
US4806569	Fish oil div c (diabetes)

016

For use in the treatment of disease, a pharmaceutical composition comprises adrenic acid (22:4 n-6 EFA) optionally in combination with γ-linolenic acid or dihomo-γ-linolenic acid and with or without 22:5 n-6 EFA as well.

Company: Efamol	Filed/Published: 5 Jul 1984
EP0132089	20:4 deficiency

017

A product for topical application against inflammatory and pruritic conditions of the skin which comprises a dermatological tar or tar-based preparation and γ-linolenic acid (GLA) or dihomo-γ-linolenic acid (DGLA) as such or in the form of an active derivative thereof.

Company: Efamol	Filed/Published: 19 Sep 1984
EP0139480	Oil + tar

018

A method of maintaining hens or other domesticated birds for egg production, comprises giving the birds feed supplemented with γ-linolenic acid or one or more higher acids in the n-6 series, in the form of the free acid or as a ester, amide, phospholipid, salt or other physiologically acceptable derivative convertible in the bird's body to, or having the effect of, the free acid.

Company: Efamol	Filed/Published: 1 Apr 1985
EP0157619	Chicken feed
US4738853	Chicken feed

019

A topical composition for skin treatment contains an anti-inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent polyunsaturated fatty acid, as such or in the form of a physiologically acceptable derivative convertible in the body thereto.

Company: Efamol	Filed/Published: 5 Aug 1985
EP0173478	Oil + steroids

020

Pharmaceutically acceptable composition comprises linoleic acid, γ-linolenic acid and/or dihomo-γ-linolenic acid and assimilable copper compounds optionally with a diluent or carrier, the acids being as such or as derivatives convertible in the body thereto. The amounts of acids or derivatives are 0.2 to 10g (calculated as γ-linolenic aicd) and of copper compounds are 0.1 to 100mg (calculated as copper).

Company: Efamol	Filed/Published: 16 Sep 1985
EP0181689	Oil + copper
US4965075	Oil + copper

021

The preparation of a composition for the treatment of benign prostatic hypertrophy wherein γ-linolenic acid or dihomo-γ-linolenic acid or both, as such or in the form of acceptable physiologically equivalent derivatives, are brought into administrable form, optionally with a carrier or diluent.

Company: Efamol	Filed/Published: 24 Feb 1986
EP0201159	Prostatic hypertrophy
US4898885	Prostatic hypertrophy

022

Gamma-linolenic acid or dihomo-γ-linolenic acid for use in the reduction of prevention of gastro-intestinal bleeding and other side effects shown by NSAIDs when administered on a continuing basis, including use in allowing said administration to be replaced by administration of said acid alone in arthritis and other conditions without exacerbation of symptoms

Company: Efamol	Filed/Published: 7 Mar 1986
EP0195570	Oil + aspirin
US4666701	Oil + aspirin

023

A method of treatment of prementrual syndrome wherein effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one more of the metabolites of alpha-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

Company: Efamol	Filed/Published: 24 Jun 1986
EP0211502	Premenstrual Syndrome

024

A composition comprises a polyunsaturated fatty acid, in particular as essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracylcine or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, the composition reducing that sensitisation.

Company: Efamol	Filed/Published: 3 Sep 1986
EP0214839	Oil + HK7
US4996233	Oil + HK7
US5589509	Oil + HK7

025

A method of prevention or treatment of diabetic neuropathy and the other long term complications of diabetes mellitus including complications in the cardiovascular system, kidneys and eyes wherein effective amounts of one or both of I) γ-linolenic acid and/or one or more of the metabolites of γ-linolenic acid (DGLA, AA, 22:4 n-6 or 22:5 n-6) and ii)18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3, 22:6 n-3) are administered against such complications as such or in the form of an ester, salt amide or other derivative convertible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.

Company: Efamol	Filed/Published: 1 Oct 1986
EP0218460	Diabetic neuropathy
US4826877	Diabetic neuropathy

026

Method of prevention or treatment of endometriosis wherein effective amounts of one or both I) γ-linolenic acid and/or dihomo-γ-linolenic acid and ii) 18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3 or 22:6 n-3) are administered against endometriosis as such or in the form of an ester, salt amide or other derivative converible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.

Company: Efamol	Filed/Published: 1 Oct 1986
EP0222483	Endometriosis
US4758592	Endometriosis

027

This invention relates to the treatment of presenile or senile dementia and in particular to the treatment of Alzheimer's disease. It is proposed that such conditions may be combatted or their effects alleviated by the administration of a physiologically acceptable lithium compound and/or of an essential fatty acid or a physiologically acceptable salt thereof and there are described herein methods of treatment of such conditions.

Company: Efamol	Filed/Published: 27 Jan 1987
US4753964	Anti-alzheimer
US4810497	Pharmaceutical compositions
EP0234733	Anti-alzheimer

028

Pharmaceutically acceptable compositions or one or more n-6 or n-3 essential fatty acids, particularly gammo-linolenic acid, dihomo-γ-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1mg to 100mg (calculated as γ-linolenic acid) and of said iron compounds 0.1mg to 10g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Company: Efamol	Filed/Published: 18 Mar 1987
EP0246734	Oil + iron
US5128152	Oil + iron
US5246726	Oil + iron div (wider claims)

029

Combinations of γ-linolenic acid (GLA) and calcium, presented for administration in assimilable dosage unit form in doses of 1mg to 100g GLA and 1mg to 20g calcium daily, for example, for the treatment of osteoporosis and other bone disorders involving calcium loss from the bones, of premenstrual syndrome, or of hypertension.

Company: Efamol	Filed/Published: 28 Aug 1987
EP0261814	Oil + calcium
US4855136	Oil + calcium

030

Treatment of the prevention of occurrence or reoccurrence of peptic ulcers by administering to a person suffering or at risk of suffering from the same, 1mg to 50g per day, advantageously 10mg to 1g per day, of one or more essential fatty acids selected from the 18:3 and higher acids of the n-6 series and the 18:4 and higher acids of the n-3 series.

Company: Efamol	Filed/Published: 22 Feb 1988
EP0283140	Peptic ulcers

031

The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation with a physiologically acceptable lithium salt.

Company: Efamol	Filed/Published: 23 Feb 1988
US4886670	Anti-viral compositions
EP0135312	Anti-viral compositions

032

The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C18-22 polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.

Company: Efamol	Filed/Published: 20 Apr 1988
EP0289204	Lithium salt-containing pharmaceutical compositions
EP0289204	Lithium salt-containing pharmaceutical compositions

033

Treatment or prevention of memory loss with a medicament consisting of an n-6 essential fatty acid selected from GLA, DGLA, AA, adrenic acid and the 22:5 n-6 acid and a n-3 essential fatty acid selected from the 18:4 n-3 and 20:4 n-3 acids, EPA, the 22:5 n-3 acid and DHA.

Company: Efamol	Filed/Published: 15 Jun 1988
EP0296751	Memory loss
US5198468	Memory loss

034

A method of treatment of schizophrenia or other chronic cerebral disorder in which cerebral atrophy is shown, is characterised in that one or more assimilable or pharmaceutically acceptable indium, caesium or cerium compounds is associated with a pharmaceutically acceptable diluent or carrier

Company: Efamol	Filed/Published: 29 Jun 1988
EP0298644	Oil + indium

035

Method of modulating androgen action in men or women to prevent or treat male pattern baldness and/or reduce or stop unwanted hair growth in areas of the body excluding the scalp, by administering topically or systemically one or more unsaturated fatty acids selected from the 18:3 and higher acids in the n-6 series and 18:4 and higher acids in the n-6 series, in amounts of 1mg to 100g, preferably 50mg to 5g, daily with the limitation that for topical administration the acid(s) are selected from γ-linolenic, dihomo-γ-linolenic acid and eicosapentanoic acid.

Company: Efamol	Filed/Published: 9 Aug 1988
EP0309086	Androgen modulation

036

There are provided lithium-containing nutritional supplements, e.g. foodstuffs, multi-vitamin/mineral preparations and parenteral and enteral alimentation solutions containing physiologically tolerable lithium compounds. There is provided the use of a physiologically tolerable lithium compound for the manufacture of an agent for use in a method of treatment of combination skin.

Company: Efamol	Filed/Published: 15 Aug 1988
EP0305097	Nutritional supplement
EP0432700	Div combination skin

037

Composition of a cyclosporin and GLA or DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.

Company: Efamol	Filed/Published: 2 Dec 1988
EP0321128	Oil + cyclosporin
US4970076	Oil + cyclosporin

038

There are provided pharmaceutical and nutritional compositions containing sodium or potassium salts of C18-22 polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to polyunsaturated fatty acid therapy, in parenteral alimentation or in food supplements. The compositions may further include a lithium salt of C18-22 polyunsaturated fatty acids.

Company: Efamol	Filed/Published: 16 Dec 1988
GB2222080	Fatty acids

039

A composition, particularly an oral composition, for improving the smoothness of the skin, wherein GLA or DGLA or both as such or in the form of physiologically acceptable and equivalent derivatives are brought into administrable form with a carrier or diluent.

Company: Efamol	Filed/Published: 7 Mar 1989
EP0334507	Skin smoothness
US4997657	Skin smoothness

040

Method of preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher n-6 series acids with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10mg and 50g of each acid.

Company: Efamol	Filed/Published: 26 May 1989
EP0347056	Oil + high vit E
EP0454102	Oil + high vit E div composition
US4977187	Oil + high vit E
US5120760	Oil + high vit E div tardive dyskinesia

041

The use of one or more of the 6-desaturated or higher essential fatty acids (EFAs) of each of the n-6 and N-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME). The co-administration of interferons with EFAs will enhance the efficacy of interferon.

Company: Efamol	Filed/Published: 30 Aug 1989
EP0364094	Myalgic encephalomyelitis
US5116871	Myalgic encephalomyelitis

042

Anti-viral wherein a linoleyl, γ-linoleyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.

Company: Efamol	Filed/Published: 11 Apr 1990
EP693498	Oil + antivirals div
EP0393920	Oil + antivirals
US5216142	Oil + antivirals
US5276020	Oil + antivirals div

043

A method of preparation of a medicament for reducing the risk of undesirable metabolites from free bodily AA on administration of AA to current deficiency thereof, wherein GLA and/or DGLA as such or in the form of a salt dissociated at physiological pH is prepared as said medicament alone or incorporated in a pharmaceutically acceptable diluent or carrier.

Company: Efamol	Filed/Published: 17 Jul 1990
EP0409559	AA + DGLA

044

The use of one or more of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid for the manufacture of a medicament for use in enhancement of the anti-viral, anti-cancer or inflammatory effects of interfons, said medicament containing or being for use with a medicament containing one or more interferons when not solely for enhancement of the effect of endogenous interferons.

Company: Efamol	Filed/Published: 2 Aug 1990
EP0416743	Oil + interferon
EP0678299	Oil + interferon div
US5580556	Oil + interferon

045

A method of preparing a medicament for treating or preventing skin damage in patients undergoing radiotherapy wherein (a) linoleic acid, or (b) γ-linolenic acid or dihomo-γ-linolenic acid, or (c) both said LA and said GLA or DGLA, are used to prepare said medicament alone or with a pharmaceutically acceptable carrier or diluent.

Company: Efamol	Filed/Published: 4 Sep 1990
EP0416855	Radiation damage

046

A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.

Company: Efamol	Filed/Published: 14 Jan 1991
EP0440341	Oil + selenium
US5116624	Oil + selenium

047

A method of preparation of a medicament for increasing one or more of the total fat and therefore energy content of mammalian and particularly human milk, the EFA content of that milk and the flow of that milk, or for preventing or reducing the normal fall in milk fat content that occurs during prolonged lactation, wherein GLA and/or DGLA is provided, alone or in a physiologically acceptable diluent or carrier, in a form administrable to the lactating female.

Company: Efamol	Filed/Published: 15 Jan 1991
EP0440347	Milk enhancement
US5264217	Milk enhancement

048

A method of manufacture of a medicament for the inhibition of phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is presented as said medicament alone or in a pharmaceutically acceptable diluent or carrier.

Company: Efamol	Filed/Published: 24 May 1991
EP0460848	Stearidonic acid
US5178873	Stearidonic acid

049

The present invention provides use of a physiologically acceptable lithium compound in the manufacture of a medicament for use in the treatment and/or prophylaxis of molluscum contagiosum. It also extends to pharmaceutical compositions comprising a physiologically acceptable lithium compound together with at least on keratolytic and/or skin penetration assisting agent and at least one pharmaceutically acceptable carrier or excipient.

Company: Efamol	Filed/Published: 30 Oct 1991
EP0484112	Molluscum contagiosum

050

Countering side effects of parenteral or fluid-diet enteral nutrition by adding one or more 6-desaturated essential fatty acids (EFAs) to parenteral or enteral composition (particularly low-fat compositions) being given, or giving them in addition to the compositions.

Company: Efamol	Filed/Published: 4 Dec 1991
EP0682878	Intestinal atrophy div
EP0490561	Intestinal atrophy

051

Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxygenase products, and lysine.

Company: Efamol	Filed/Published: 8 Jan 1992
US5145686	Topical pharmaceutical compositions
US5145686	Topical pharmaceutical compositions
EP0085579	Topical compositions

052

Reduction of urinary calcium excretion in humans or animals by the administrative of GLA or DGLA as much or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar form, is also useful in the treatment of nephrocalcinosis, renal stones and osteoporosis.

Company: Efamol	Filed/Published: 28 May 1992
EP0517425	Calcium excretion
US5318991	Calcium excretion

053

A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-γ-linolenyl-glyc erol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.

Company: Efamol	Filed/Published: 28 May 1992
EP0520624	DLMG
US5328691	DLMG
US5552150	DLMG div a
US5620701	DLMG div b
US5614208	DLMG div c

054

Use of one or more EFA's or the n-6 series and/or n-3 series in the preparation of a medicament for relieving the symptoms of AIDS, preventing the progression of AIDS or the development of symptoms of AIDS in HIV infected persons, and a method of treatment of such persons.

Company: Efamol	Filed/Published: 20 Jul 1992
EP0524796	AIDS

055

Gamma-linolenic acid and/or dihomo-γ-linolenic acid is used in the prparation of a medicament for inhibiting occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.

Company: Scotia	Filed/Published: 26 Nov 1992
EP0676197	Arterial reocclusion div
EP0551729	Arterial reocclusion
US5378732	Arterial reocclusion

056

Gamma-linolenic (GLA) and/or dihomo-γ-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.

Company: Scotia	Filed/Published: 19 May 1993
EP0572159	Vulvar dystrophy
US5380757	Vulvar dystrophy

057

Increasing gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in the treatment of osteoporosis.

Company: Scotia	Filed/Published: 16 Aug 1993
EP0585026	Calcium absorption
US5618558	Calcium absorption

058

Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexainoic acid (DHA) or docosapentaenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.

Company: Scotia	Filed/Published: 16 Aug 1993
EP0585027	Tissue calcification
US5516801	Tissue calcification

059

Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acids(s) or a proportion thereof are administered in the form of lithium salts, and thereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keepin the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4 - 0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered at lithium salts, a corresponding proportion of said levels. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels.

Company: Scotia	Filed/Published: 19 Aug 1993
EP0585057	Intravenous Li EFA (monitoring)
US5508307	Intravenous Li EFA (monitoring)

060

Method of safe intravenous administration of fatty acids or salts or other derivatives of fatty acids or conjugated fatty acids, whereby heparin or related compound in a dose of 1,000 - 2,000 IU or equivalent anticoagulant dose of heparin-like protein or peptide is administered suβ-cutaneously or intravenously prior to infusion of the fatty acid, or where 1 - 100 IU/ml, preferably 10 to 20 IU/ml heparin or related compound, or equivalent anticoagulant dose of heparin-like protein or peptide is added to the infusion fluid carrying the fatty acid, or where both pretreatment with heparin-like protein or peptide and simultaneous administration are combined. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels.

Company: Scotia	Filed/Published: 19 Aug 1993
EP0585058	Intravenous Li EFA (heparin)

061

The negative symptoms of schizophrenia and/or low cell membrane levels of EFAs may be treated with a combination of arachidonic acid and docosahexaenoic acid.

Company: Scotia	Filed/Published: 22 Nov 1993
EP0733360	Schizophrenia (low EFA membr.)
EP0599576	Schizophrenia (low EFA membr.)
US5516800	Schizophrenia (low EFA membr.)

062

Cholesterol fatty acid esters, where the fatty acid is chosen from an essential fatty acid, or from parinaric or columbinic acids may be used in therapy, especially in the treatment of cancer and cardiovascular disease.

Company: Scotia	Filed/Published: 29 Dec 1993
EP0606012	Cholesterol esters
US5604216	Cholesterol esters

063

Triglycerides with at least two different acids chosen from 6-desaturated essential fatty acids and oleic acid, useful in nutrition and in medicine.

Company: Scotia	Filed/Published: 18 Jan 1994
EP0609001	Mixed triglycerides

064

A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from γ-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acid is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

Company: Scotia	Filed/Published: 18 Jan 1994
EP0611569	Tri-GLA etc.
US5670540	Tri-GLA etc.

065

Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionising radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Company: Scotia	Filed/Published: 26 Jan 1994
EP0609064	Internal radiation damage
US5583159	Internal radiation damage
US5663202	Internal radiation damage

066

A phospholipid comprising two different unsaturated fatty acids, the fatty acids being selected from the twelve n-6 and n-3 essential fatty acids, oleic acid, parinaric acid and combinic acid.

Company: Scotia	Filed/Published: 27 Jan 1994
EP0609078	Phospholipids
US5466841	Phospholipids

067

A method of preparation of a medicament for treatment of one or more of the following conditions when a herpes virus, particularly the herpes simplex virus, is involved in the causation thereof: chronic fatigue syndrome; depression; irritable bowel syndrome; fibromyalgia; headaches; anxiety; panic disorder; narcolepsy; Tourette's disorder; kleptomania; bulimia nervosa; obsessive compulsive disorder; attention deficit disorder with hyperactivity; cataplexy; psychopathic disorder; gingivitis; dental caries; wherein a drug effective against such virus is used as an active ingredient of said medicament.

Company: Scotia	Filed/Published: 16 Feb 1994
EP0615750	Uses of anti-virals

068

A method of treating viral infections, in particular retroviral infections, especially those with the HIV group of viruses, by destroying virus-infected cells in the body through administration of unsaturated fatty acids, particularly as lithium salts.

Company: Scotia	Filed/Published: 9 Mar 1994
EP0615752	Viral cells

069

Preparation of a formulation for mitigating ill effects of smoking, wherein one or more of the n-6 EFAs selected from GLA, DGLA and AA, and one or more of the n-3 EFAs selected from SA, 20:4 n-3, EPA, DPA or DHA are used, preferably so that the daily dose of each fatty acid is within the range 1mg to 100g/day. The formulation may in many other purposes be used in the treatment or prevention of ageing of the skin of smokers.

Company: Scotia	Filed/Published: 15 Mar 1994
EP0615753	Smokers
US5562913	Smokers

070

A natural vitamin E preparation, i.e. vitamin E extracted from natural sources, comprising one or more of the alpha-,β-, γ- and delta-tocopherol froms, either as the tocopherol itself, or as a derivative, such as acetate, in which the total concentration of Wendt PAHs is less than 100 ppb.

Company: Scotia	Filed/Published: 2 Sep 1994
EP0641790	Low PAH tocopherols
US5635189	Low PAH tocopherols

071

Polyunsaturates, that is to say triply or higher enthylenically unsaturated organic materials, especially essential fatty acids, are stabilised by the addition of at least one essential oil. The essential oil is preferably chosen from thyme oil, oregano oil, pepper oil and clove oil.

Company: Scotia	Filed/Published: 18 Oct 1994
WO9511289	Stabilisation with essential oils

072

An NSAID in the form of compound with an essential fatty acid or essential fatty acid alcohol, particularly an NSAID as listed in categories 1 to 9 herein. Further, a method of preparation of a medicament for the treatment including prophylatic treatment of rheumatoid arthritis, osteoarthritis and related disorders ; dysmenorrhoea ; dementias ; including Alzheimer's disease ; or any other inflammatory or other conditions specified herein, wherein the said NSAID is used.

Company: Scotia	Filed/Published: 1 Mar 1995
EP0675103	EFA NSAIDS
US5603959	EFA NSAIDS

073

Ascorbyl-GLA or Ascorbyl-DGLA in medicaments for treatment of asthma and other disorders.

Company: Scotia	Filed/Published: 1 Mar 1995
EP0675120	Use of ascorbyl-gamma-linolenate or a ascorbyl-dihomo-gamma-linolenate for the treatment of asthma, cancer, cardiovascular and inflammatory disorders.

074

The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of composition comprising a topically acceptable excipient and an effective amount of lithium salt.

	Filed/Published: 13 Apr 1995
US5594031	Skin treatment
EP0132126	Skin treatment
EP0132126	Skin treatment

075

An N-alkylpolyhydroxyamine salt of an n-6 or n-3 essential fatty acid (EFA) that is beyond the 6-desaturation step, or of any polyunsaturated fatty acid, other than those belonging to the n-6 and n-3 series, having 16 - 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, the salt being formed with the fatty acid either as such or in the form of a covalent derivative, through the carboxyl group, of a bifunctional compound itself having a free acid function.

Company: Scotia	Filed/Published: 20 Apr 1995
WO9633155	Sugar-amine salt

076

Compounds being polyethylene glycol derivatised, pharmacologically acceptable, tumour locating dihydro or tetrahydro porphyrins of formulae (4,5 and 6), wherein R1n may be -OH but in at least two instances is a chain of formula (-0-Xp-[ch2CH20]M-Y)N wherein n = 1 to 3, m = 5 to 250 and p = 0 to 1; the group Y may be a C1-C12 alkyl or acyl group but preferably a methyl group X may be present or absent, but if present may be of the following alternative forms: R2 = -C(C=0)-CH2)q-0- where q = 1 to 5; R3 = -CH2-CH(OH)-CH2)s-0- where s = 1 to 4; R4 = -(C=0)CH2)t-(C=0)-0- where t = 1 to 4. Improved tumour localisation of polyether-substituted photosensitising compounds is given leading to their more efficient uptake into tumour cells. Lower overall doses of drug give an improved side-effect profile of the treatment especially with regrd to skin photosenitisation.

Company: Scotia	Filed/Published: 2 May 1995
WO9529915	PEG dihydro HK7

077

A method of treatment or prevention of, or a method of making medicament for the treatment or prevention of, hormone replacement therapy-associated breast pain in peri- or post-menopausal women, wherein an n-6 or n-3 series essential fatty acid is used as an active of said medicament or in said therapy, optionally with a natural synthetic replacement therapy oestrogen.

Company: Scotia	Filed/Published: 14 Sep 1995
EP0707850	Hormone replacement therapy

078

A milk or milk-derived product, enriched or supplemented with GLA and/or DGLA, the milk or milk derived product comprising 100mg to 30g/100ml preferably 150mg to 5g/100ml and very preferably 200mg to 2g per 100ml of GLA and/or DGLA and optionally further comprising fatty acids such as AA, SA, EPA, or DHA in amounts from 1mg to 30g.100ml.

Company: Scotia	Filed/Published: 9 Nov 1995
EP0711503	Fortified milk

079

A fruit juice enriched or supplemented with GLA and/or DGLA, the fruit juice comprising 1mg to 30g/100ml, preferably 10mg to 15g/100ml and very preferably 100mg to 2g/100ml of GLA and/or DGLA and optionally further comprising other fatty acids such as AA, SA, or EPA, or DHA in amounts from 1mg to 30g/100ml, preferably 10mg to 15g/100ml and very preferably 100mg to 2g/100ml.

Company: Scotia	Filed/Published: 10 Nov 1995
EP0713653	Fortified fruit juice

080

Use of 6-desaturated n-6 fatty acids, especially γ-linolenic acid (GLA), dihomo-γ-linolenic aicd (DGLA) or arichadonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sobitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including phophylactic treatment), the lonγ-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.

Company: Scotia	Filed/Published: 31 Jan 1996
EP0694302	EFAs & aldose reductase inhibitors

081

Triglycerides with two or three different fatty acids chosen from the twelve essential fatty acids, oleic acid and other fatty acids containing 8 to 26 carbon atoms, useful in nutrition and in medicine.

Company: Scotia	Filed/Published: 3 Apr 1996
WO9631457	LA/ALA (parent EFA triglycerides)

082

Compounds of 1,3-propane dial linked structure (I), when for use in therapy, where R1 is an acyl of fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans bonds, and R2 is hydrogen, or an acyl or fatty alcohol group as R1 the same or different, or any other nutrient, drug or other bioactive residue.

Company: Scotia	Filed/Published: 1 May 1996
WO9634846	Diols (mutual lipophilic prodrugs)

083

Niacin is a compound, per se or for use in therapy, of structure (I), where B is -C(=0)- (nicotinic acid) or -CH2-0- (niacin alcohol), the "link" C which is optional is a diol or hydroxy carboxylic acid or dicarboxylic acid residue, and D is a fatty acid or fatty acid alcohol residue, the links between B and C and C and D being ester links.

Company: Scotia	Filed/Published: 1 May 1996
WO9634858	Niacin esters

084

Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linleic acid, or columbinic acid, or parinaric acid and R2 is as R1 the same of different, or any other nutrient, drug or other bioactive residue released as the active in the body and R3 is either hydrogen, fully hydrocarbon, or containing heteroatoms, preferably an alkyl group particularly a C1-C4 alkyl group.

Company: Scotia	Filed/Published: 1 May 1996
WO9634855	1-Carbon linkers

085

A method and means of identifying individuals genotypically predisposed to schizophrenia, by establishing the presence of abnormal alleles in the promoter region of the cPLA2 gene of chromosome 1.

Company: Scotia	Filed/Published: 24 Jul 1996
WO9704127	Schizophrenia gene (diagnosis)

086

Use of AA or DHA, desirably both, or in either case one or more precursor fatty acids, for the preparation of a medicament for treatment (including prophylaxis), by administration to children or pregnant women of dyspraxic or, specifically, poor fine and gross motor skills in dyspraxia or alternatively poor fine and gross motor skills in non-dyspraxic individuals, and such treatment and medicament in themselves.

Company: Scotia	Filed/Published: 27 Aug 1996
WO9808501	Dyspraxia

087

As chemical products or as water soluble fatty acid derivatives in nutritional, cosmetic of pharmaceutical formulations, esters of polyethylene glycol in which the polyethylene glycol chain is terminated, at one end by a polyunsaturated fatty acyl group preferably C18 - C22 and at the other end by a C1-C4 alkyl group preferably a methyl group.

Company: Scotia	Filed/Published: 19 Mar 1997
WO9735593	PEG fatty acid esters

088

Niacin in the form of a topical preparation, both as such and when incorporated in devices for application to the skin; the devices themselves; diagnosis or monitoring or schizophrenia using the preparations or devices; and manufacture of medicaments for such monitoring and diagnosis.

Company: Scotia	Filed/Published: 29 May 1997
WO9745145	Schizophrenia diagnosis (niacin)

089

The use of preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with aa carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used.

Company: Scotia	Filed/Published: 2 Jul 1997
WO9809621	Chemotherapy side effects

090

This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia

Company: Scotia	Filed/Published: 26 Aug 1997
WO9808501	Use of arachidonic acid and/or docosahexanoic acid for the treatment of dyspraxia

091

A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.

Company: WWK Trust	Filed/Published: 27 Aug 1997
WO9808520	Pain treatment

092

Use of at least one n-6 essential fatty acid and/or at least one n-3 essential fatty acid and/or at least one n-3 essential fatty acid in the preparation of a medicament for countering red cell damage and/or tissue hypoxia during radiotherapy, and/or consequent fatigue and the method of countering such by its administration.

Company: Scotia	Filed/Published: 11 Sep 1997
WO9816215	Use of essential fatty acids for the treatment and prevention of radiation damage to erythrocytes

093

The isopropyl esters of fatty acids with 16-26 carbon atoms and two to six double bonds in either the cis or the trans configuration.

Company: Scotia	Filed/Published: 17 Sep 1997
WO9813330	Esters of unsaturated fatty acids

094

A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present

Company: Scotia	Filed/Published: 7 Oct 1997
WO9816216	Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

095

Phosphatidylethanolamine in the form of a preparation derived from egg yolk and containing more than 20% by weight of the phosphatidylethanolamine, preferably more than 40%, very preferably more than 60%, and most preferably more than 70%.

Company: Scotia	Filed/Published: 8 Oct 1997
WO9816233	Formulations containing phosphatidylethanolamine

096

The invention relates to the use of a physiologically tolerable lithium compound for the manufacture of a medicament for use in combatting human papilloma virus infections.

Company: Scotia	Filed/Published: 21 Oct 1997
WO9817288	Lithium-containing medicament for combatting papilloma virus infections

097

Compounds of 1,2-propane diol linked structure (I), when for use in therapy, wherein R<1> or R<2> comprises an acyl or fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans double bonds, or any other nutrient, drug or other bioactive residue, such that at least one of R<1> or R<2> comprises an acyl or fatty alcohol group as defined above, and wherein where both R<1> or R<2> comprises acyl or fatty alcohol groups they may be the same or different.

Company: Scotia	Filed/Published: 23 Oct 1997
WO9818751	Presentation of bioactives

098

A non-aqueous formulation of a fatty acid anhydride conforming to the general formula R1-O-R2, where R1 and R2 are polyunsaturated (C 16 -C 26 ) fatty acid acyl groups, is particularly efficacious for the presentation of the corresponding acids in therapy or as food additives. Ordinary or mixed acid anhydrides are chosen from a group of acids including octa(poly)enoic, eicosa(poly)enoic and docosa(poly)enoic acids. Preferred acids are those with two to six cis double bonds.

Company: Scotia	Filed/Published: 10 Mar 1998
WO9840059	Presentation of Polyunsaturated Fatty Acids

099

Medicament manufacture for depression or anxiety using compositions of natural antioxidants, or compositions of essential fatty acids (docosahexaenoic acid, DHA) optionally with essential nutrients and/or natural antioxidants.

Company: Scotia	Filed/Published: 23 Apr 1998
WO9848788	Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

100

Compositions of glucosamine and an essential fatty acid, especially one or more of the "delta-6-desaturated" n-6 and n-3 essential fatty acids such as GLA, DGLA, SA, EPA, and DHA, other than compositions comprising chondroitin sulphate; and their use in inflammatory joint conditions including osteoarhitis and arthritis.

Company: Scotia	Filed/Published: 18 May 1998
WO9852556	Glucosamine fatty acid compositions and their use

101

A synergistic combination therapy comprises the administration of i) at least one of an essential fatty acid (EFA), particularly γ-linolenic or dihomo-γ-linolenic acid and ii) a biocompatible disulfide, preferably a-lipoic acid. The sulfide is thought to act by providing improved incorporation of EFAs into cell membrane phospholipids rather than as merely an antioxidant. Compositional dosage forms are disclosed, optionally also comprising vitamins for use as medicaments, nutritional supplements or functional foods. The combination is claimed for use in the treatment of a wide range of disorders including diabetic, inflammatory, neurodegenerative and cardiovascular conditions.

Company: Viatris (US)	Filed/Published: 22 Jul 1998
WO9904782	Combination Therapy

102

Tamoxifen and gammalinolenic acid giving strong synergistic action in cancer management and preparation of medicaments therefor.

Company: Scotia	Filed/Published: 24 Feb 1999
WO9808501	Cancer management with tamoxifen and gamma-linolenic acid

103

Pharmaceutical preparations which comprise compounds which can be metabolised by FACL enzymes are disclosed. Those compounds metabolised by FACL-4 to Coenzyme A derivatives are preferred. Highly unsaturated fatty acids (HUFAs) and their derivatives are suitable such compounds. The most preferred compound is eicosapentaenoic acid. The psychiatric disorders to be treated are schizophrenia, schizo-affective disorders, mania, depression, bipolar disorders, ADHD, anxiety and panic attacks, social phobias, Alzheimer's disease and other dementias, epilepsy, Parkinson's disease, stroke transient ischemic attack, multiple sclerose, Huntington's disease, and other neurodegenerative disorders.

Company: Laxdale	Filed/Published: 20 Jan 2000
WO0044360	Drugs for treatment of psychiatric and brain disorders

104

Use of drugs which are able to inhibit CoAIT in the treatment of, or in the manufacture of a medicament for the treatment of psychiatric disorders.

Company: Scarista	Filed/Published: 3 Mar 2000
WO0056295	Regulators of coenzyme-A-independent transacylase as psychotropic drugs

105

Orally administrable formulations containing a vitamin B12 component, preferably hydroxocobalamin, and phenylalanine are described. They may be taken at a specified daily dosage to provide 50 to 5000 mg phenylalanine per day and 0.2 to 50 mg of vitamin B12 component. They are used to treat pain or chronic fatigue syndrome. Other drugs or essentiel nutrients may be added such as folic acid, glucosamine or an anti-depressant drug as appropriate.

Company: Laxdale (Kilgowan)	Filed/Published: 23 Mar 2000
WO0056404	Formulations for treatment of pain comprising vitamin B12 and phenylanine

106

A variety of conditions is known wherein vitamin B12 is deficient, or wherein the administration of vitamin B12 is beneficial. Classically, once detected and if appropriate, these have been treated by the parenteral administration of vitamin B12 as oral administration is believed to be ineffective. Available oral preparations of vitamin B12 all contain cyanocobalamin which is less desirable than hydroxocobalamin. In accordance with the invention, effective oral formulations are provided which include, in addition to the hydroxocobalamin, folic acid or other folate precursor. The formulation for oral administration should be such as to provide, for a given daily dose, 0.5 to 50 mg hydroxocobalamin and 0.5 to 50 mg folic acid

Company: Laxdale (Kilgowan)	Filed/Published: 23 Mar 2000
WO0056295	Oral combinations of hydroxocobalamin and folic acid

107

The combined application of at least one essential fatty acid of the n-6 or n-3 series, optionally together with further essential fatty acid(s) of the n-6 or n-3 series, together with one or more homocysteine lowering agent. The homocysteine lowering agent is selected from vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

Company: Scarista	Filed/Published: 11 Jul 2000
WO0103696	Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents

108

A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.#The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion

Company: Laxdale	Filed/Published: 12 Oct 2000
WO0126623	Treatment of fatigue, head injury and stroke

109

This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility

Company: Personal	Filed/Published: 6 Apr 2001
WO0176568	Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

110

Eicosapentaenoic acid or any appropriate derivative (EPA) is disclosed in combination with arachidonic acid (AA) or an AA precursor, selected from DGLA and GLA, to give a pharmaceutical formulation

Company: Laxdale	Filed/Published: 20 Jun 2001
WO0202105	Therapeutic combinations of fatty acids

111

Nutritional and pharmaceutical formulations comprising in combination vitamin K and a source of at least one essential fatty acid (EFA) as the essential ingredients, and foodstuff containing EFA(s) and an artificially elevated quantity of vitamin K are provided for the treatment or prevention of a variety of diseases or conditions

Company: Ensay	Filed/Published: 20 Jun 2001
WO0201969	Vitamin K and essential fatty acids

112

The co-administration of ubiquinone (coenzyme Q) with eicosapentaenoic acid, which may be supplemented with or replaced by one or more of the unsaturated fatty acids γ-linolenic acid, dihomoγ-linolenic acid, arachidonic acid and stearidonic acid. The fatty acids docosahexaenoic acid and linoleic acid should be present in less than 10%

Company: Laxdale	Filed/Published: 9 May 2002
WO02096408	Coenzyme Q and EPA

113

The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administration of the fatty acid alone

Company: Laxdale	Filed/Published: 9 May 2002
WO02089787	Potentiation of therapeutic effects of fatty acids

114

Eicsapentaenoic acid (EPA) is used in the treatment of anorexia nervosa, bulimia and related clinical syndromes

Company: Laxdale	Filed/Published: 25 Mar 2004
WO2004024136	EPA for treating anorexia and bulimia

115

Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.

Company: Laxdale Ltd	Filed/Published: 17 Jun 2004
WO2004050913	Treatment of Huntington's disease with EPA

116

Use of eicosapentaenoic acid in the treatment or prevention of psoriasis or other disorder.

Company: Pabay Investments	Filed/Published: 5 Aug 2004
WO2004064716	Psoriasis and eicosapentaenoic acid

All copyrights acknowledged

Contact Peter Lapinskas

Last updated: 1 April 2008